Denese Carol Marks

Denese Carol Marks

Auto-generated profile, based on publicly available information

Denese Carol Marks

Australian Red Cross Lifeblood, 17 O’Riordan Street, Alexandria, NSW 2015, Australia

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1992 in Leukemia Research
Verified
Journal Article
Closed access
DMDenese C. Marks
Denese C. Marks
LBLarissa Belov
Larissa Belov
MDMary W. Davey
Mary W. Davey
RDRoss A. Davey
Ross A. Davey
AKAntony D. Kidman
Antony D. Kidman


17 February 2014 in Transfusion
Verified
Journal Article
Closed access
PDF file
LJLacey Johnson
Lacey Johnson
CCCraig P. Coorey
Craig P. Coorey
DMDenese C. Marks
Denese C. Marks

5 November 2014 in Transfusion
Verified
Journal Article
Closed access
PDF file
LJLacey Johnson
Lacey Johnson
MRMichael C. Reade
Michael C. Reade
RHRyan A. Hyland
Ryan A. Hyland
STShereen Tan
Shereen Tan
DMDenese C. Marks
Denese C. Marks

14 December 2016 in Journal of Blood Transfusion
Verified
Journal Article
Open access
PDF file
JAJason P. Acker
Jason P. Acker
DMDenese C. Marks
Denese C. Marks
WSWilliam P. Sheffield
William P. Sheffield
Blood is donated either as whole blood, with subsequent component processing, or through the use of apheresis devices that extract one or more components and return the rest of the donation to the donor. Blood component therapy supplanted whole blood transfusion in industrialized countries in the middle of the twentieth century and remains the standard of care for the majority of patients receiving a transfusion. Traditionally, blood has been processed into three main blood products: red blood cell concentrates; platelet concentrates; and transfusable plasma. Ensuring that these products are of high quality and that they deliver their intended benefits to patients throughout their shelf-life is a complex task. Further complexity has been added with the development of products stored under nonstandard conditions or subjected to additional manufacturing steps (e.g., cryopreserved platelets, irradiated red cells, and lyophilized plasma). Here we review established and emerging methodologies for assessing blood product quality and address controversies and uncertainties in this thriving and active field of investigation.

17 April 2014 in Transfusion
Verified
Journal Article
Closed access
PDF file
HSHannah E. Salvin
Hannah E. Salvin
SPSant-Rayn Pasricha
Sant-Rayn Pasricha
DMDenese C. Marks
Denese C. Marks
JSJoanna Speedy
Joanna Speedy